Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant

Therapeutic Drug Monitoring

Volumn 30, Issue 5, 2008, Pages 570-575

  Weber, Lutz T ^a,b   Hoecker, Britta ^a   Armstrong, Victor W ^b   Oellerich, Michael ^c   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Long term pharmacokinetics; Mycophenolate mofetil; Mycophenolic acid; Pediatric renal transplantation

Indexed keywords

CYCLOSPORIN A; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISONE; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; MULTICENTER STUDY; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG ADMINISTRATION; INFANT; INTERNATIONAL COOPERATION; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PRESCHOOL CHILD; STANDARDS; TIME; TRANSPLANTATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTERNATIONALITY; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 55249127693     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31818752d9     Document Type: Article

References (28)

1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
2. The NAPRTCS 2006 Annual Report. Available at: http;//web.emmes.com/study/ ped/index.htm. Accessed June 14, 2006.
3. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
4. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol. 1998;9:1511-1520.
5. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation; a longitudinal study in pediatric patients. Ther Drug Monit. 1999;21:498-506.
6. Oellerich M, Shipkova M, Schütz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation; implications for therapeutic drug monitoring. Ther Drug Monit. 2000;22:20-26.
7. Filler G, Zimmering M, Mai I. Pharmacpkinetics pf myoophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14:100-104.
8. David-Neto E, Pereira Araujo LM, Sumita NM, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol. 2003;18:266-272.
9. Van.Qelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantatton. Ther Drug Monit. 2006;28:145-154.
10. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharrnacodynamie relationship for total and free mycophenolic acid in pediatric renal transplant recipients; a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768
11. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-1083.
12. Bunchman T, Navafro M, Broyer M, et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol. 2001;16:978-984.
13. Höcker B, Weber LT, Bunchman T, et al. Tricontinental MMF Suspension Study Group. Mycophenolate mofetil suspension in pediatric renal transplantation; three-year data from the tricontinental trial. Pediatr Transplant. 2005;9:504-511.
14. PHARMout Laboratories, Inc. Final Interim Bioanalytical Report for Roche MYCS2675, November 23, 1999.
15. Zar JH. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice Hall; 1984.
16. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
17. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
18. Sanquer S, Breil M, Baron C, et al. Trough blood concentrations in longterm treatment with mycophenolate mofetil. Lancet. 1998;351:1557.
19. Shaw LM, Kaplan B, DeNofrio D, et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22:14-19.
20. Schuetz EG, Hazelton GA, Hall J, et al. Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem. 1986;261:8270-8275.
21. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067.
22. Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
23. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
24. Gregoor PJ, de Sévaux RG, Hené RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
25. Pou L, Brunei M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit. 2001;23:35-38.
26. Filler G, Lepage N, Delisle B, et al. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit. 2001;23:514-519.
27. Ohio L, Ferraresso M, Viganò SM, et al. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. Transplant Proc. 2005;37:856-858.
28. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503.